Related Experiment Video
Updated: May 22, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Next-Generation Coronavirus Disease 2019 Vaccines: Clinical Data and Future Directions
1Center for Virology and Vaccine Research and Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 330 Brookline E/CLS-1037, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Abstract:
Current coronavirus disease 2019 (COVID-19) vaccines have prevented millions of deaths since the beginning of the pandemic. Yet, current vaccines have critical limitations: (1) they elicit poor mucosal immune responses with reduced protection against infection and viral transmission, (2) immune responses wane quickly, and (3) new immune evasive severe acute respiratory syndrome coronavirus 2 variants continue to emerge. Next-generation vaccines aim to induce improved mucosal immunity via mucosal administration, and to elicit a greater duration and breadth of immune responses through new platforms like self-amplifying RNA. This review focuses on next-generation COVID-19 vaccines that have publicly available clinical data and are most likely to proceed in further development.
Insights
Next-generation COVID-19 vaccines aim to improve mucosal immunity and broaden protection against emerging variants. These advanced vaccines utilize new platforms like self-amplifying RNA for enhanced durability and effectiveness.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Current COVID-19 vaccines have saved millions of lives but have limitations.
- Existing vaccines show poor mucosal immunity, leading to reduced protection against infection and transmission.
- Immune responses to current vaccines wane rapidly, and new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants evade immunity.
Purpose of the Study:
- To review next-generation COVID-19 vaccines with publicly available clinical data.
- To highlight vaccines likely to advance in development for improved COVID-19 prevention.
Main Methods:
- Review of clinical data for next-generation COVID-19 vaccine candidates.
- Focus on vaccines employing novel platforms and administration routes.
Main Results:
- Next-generation vaccines aim to enhance mucosal immunity through mucosal administration.
- New platforms, such as self-amplifying RNA, are being explored for longer and broader immune responses.
- Development focuses on overcoming limitations of current vaccines against infection and transmission.
Conclusions:
- Next-generation COVID-19 vaccines show promise in addressing the limitations of current vaccines.
- These advanced vaccines are expected to offer improved protection against infection, transmission, and emerging SARS-CoV-2 variants.
- Further development of these vaccines is crucial for long-term pandemic control.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
10:25Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Viral Mutations
Targeted Cancer Therapies
There are several types of targeted therapies against...
Vaccinations